Pictet Asset Management Sa Mirati Therapeutics, Inc. Transaction History

Pictet Asset Management Sa

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$41.27 - $98.62 $9.75 Million - $23.3 Million	-236,241 Reduced 98.03%	4,739 $215,000
Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $120,963 - $176,261	2,033 Added 0.85%	240,980 $16.8 Million
Q2 2022 Aug 09, 2022	SELL	$39.16 - $88.71 $5.49 Million - $12.4 Million	-140,129 Reduced 36.97%	238,947 $16 Million
Q1 2022 May 13, 2022	BUY	$75.82 - $150.97 $5.98 Million - $11.9 Million	78,807 Added 26.25%	379,076 $31.2 Million
Q4 2021 Feb 10, 2022	BUY	$132.01 - $190.29 $6.62 Million - $9.55 Million	50,164 Added 20.06%	300,269 $44 Million

Q3 2021 Nov 12, 2021	BUY	$132.13 - $177.45 $33 Million - $44.4 Million	250,105 New	250,105 $44.2 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Pictet Asset Management Sa, based on Form 13F filings with the SEC.

Stay updated on Pictet Asset Management Sa with notifications on news.